USMLE® Step 2 CK · chapter REPRO

Gynecology & Reproductive Health: USMLE® Step 2 CK topics

18 topics. Each one opens a review page with its guideline basis and key clinical sections, then links the QuestionBank questions, ChartWalk flowchart, FlashCards and ImageBank plates that share its code.

1. Abnormal uterine bleeding — PALM-COEIN & age-based workup

   REPRO-AUB-0131 questions · Review Book p. 366 · 2018 FIGO PALM-COEIN

2. Adnexal masses, ovarian cysts & torsion

   REPRO-OVCYST-019 questions · Review Book p. 375 · ACOG Practice Bulletin 174 Adnexal Masses (2016, reaffirmed); ACOG CO 783 Adnexal Torsion (2019); ACR O-RADS US v2022

3. Amenorrhea — primary & secondary workup algorithm

   REPRO-AMEN-0163 questions · Review Book p. 367 · Current evaluation of amenorrhea: a committee opinion (ASRM, 2024); Evidence-based guideline: Premature Ovarian Insufficiency (international 2024 update; ASRM publication 2025)

4. Breast cancer — types, receptor status & targeted therapy

   REPRO-BRCA-0197 questions · Review Book p. 387 · 2023 ASCO/CAP HER2 Testing in Breast Cancer Guideline Update

5. Breast mass, nipple discharge & screening by age

   REPRO-BRMASS-0157 questions · Review Book p. 385 · 2025 ACR Appropriateness Criteria Female Breast Cancer Screening

6. Cervical cancer screening, abnormal Pap & treatment

   REPRO-CERV-0159 questions · Review Book p. 378 · 2019 ASCCP Risk-Based Management Guidelines + updates through 2023; 2026 ACOG Committee Statement 28, Screening for Cervical Cancer

7. Contraceptive contraindications, IUD myths & emergency contraception

   REPRO-CONTRA-0238 questions · Review Book p. 361 · 2024 CDC US Medical Eligibility Criteria for Contraceptive Use (MEC); 2024 CDC US Selected Practice Recommendations for Contraceptive Use (Emergency Contraception)

8. Contraceptive method selection & effectiveness

   REPRO-CONTRA-0111 questions · Review Book p. 360 · 2024 CDC US Medical Eligibility Criteria for Contraceptive Use (MEC); 2024 CDC US Selected Practice Recommendations for Contraceptive Use

9. Endometrial cancer — postmenopausal bleeding to treatment

   REPRO-ENDCA-0143 questions · Review Book p. 380 · FIGO 2023 endometrial cancer staging

10. Endometriosis — diagnosis & management

    REPRO-ENDOM-0125 questions · Review Book p. 372 · 2026 ACOG Clinical Practice Guideline 11: Diagnosis of Endometriosis; 2022 ESHRE Endometriosis Guideline

11. Hereditary breast/ovarian cancer syndromes

    REPRO-HERED-0127 questions · Review Book p. 383 · 2024 NCCN Genetic/Familial High-Risk Assessment — Breast/Ovarian/Pancreatic

12. Infertility — evaluation of the couple

    REPRO-INFERT-0138 questions · Review Book p. 371 · 2019 ACOG Committee Opinion 781

13. Leiomyomas (fibroids) — evaluation & management

    REPRO-FIBR-011 questions · Review Book p. 374 · 2021 ACOG Practice Bulletin 228

14. Menopause, hormone therapy & genitourinary syndrome

    REPRO-MENO-0156 questions · Review Book p. 377 · 2022 NAMS Hormone Therapy Position Statement; 2023 NAMS Nonhormone Therapy Position Statement

15. Ovarian cancer — masses, tumor markers & staging

    REPRO-OVCA-0129 questions · Review Book p. 382 · 2016 ACOG Practice Bulletin 174 Adnexal Masses

16. PMOS (formerly PCOS) — diagnosis & management

    REPRO-PCOS-0128 questions · Review Book p. 369 · International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023); Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome (PPCOS II, 2014)

17. Sexual assault protocol & rare gynecologic entities

    REPRO-MISC-019 questions · Review Book p. 389 · 2019 ACOG Committee Opinion 777 Sexual Assault; 2021 CDC STI Treatment Guidelines

18. Vaginitis, cervicitis & STI treatment differential

    REPRO-VAGIN-0145 questions · Review Book p. 363 · 2021 CDC Sexually Transmitted Infections Treatment Guidelines (current CDC online guidance)

Written and clinically reviewed by TheCodexes.com (editorial policy). Guideline citations are the primary sources each topic follows.